|
gptkbp:instanceOf
|
gptkb:antipsychotic_medication
|
|
gptkbp:approvalYear
|
1997
|
|
gptkbp:approvedBy
|
gptkb:FDA
|
|
gptkbp:ATCCode
|
N05AH04
|
|
gptkbp:brand
|
gptkb:Seroquel
gptkb:Seroquel_XR
|
|
gptkbp:CASNumber
|
111974-69-7
|
|
gptkbp:contraindication
|
hypersensitivity to quetiapine
|
|
gptkbp:discoveredBy
|
gptkb:AstraZeneca
|
|
gptkbp:drugInteraction
|
CYP3A4 inhibitors
CYP3A4 inducers
central nervous system depressants
|
|
gptkbp:eliminationHalfLife
|
about 6 hours
|
|
gptkbp:excretion
|
urine
feces
|
|
gptkbp:form
|
extended release tablet
immediate release tablet
|
|
gptkbp:hasMolecularFormula
|
C21H25N3O2S
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:mechanismOfAction
|
gptkb:alpha-1_adrenergic_receptor_antagonist
dopamine D2 receptor antagonist
serotonin 5-HT2A receptor antagonist
muscarinic receptor antagonist
histamine H1 receptor antagonist
|
|
gptkbp:metabolism
|
gptkb:CYP3A4
liver
|
|
gptkbp:overdoseSymptoms
|
hypotension
tachycardia
somnolence
|
|
gptkbp:patentExpired
|
2011 (US)
|
|
gptkbp:pregnancyCategory
|
C (US)
|
|
gptkbp:riskFactor
|
suicidal thoughts
QT prolongation
neuroleptic malignant syndrome
tardive dyskinesia
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
gptkb:orthostatic_hypotension
constipation
dizziness
weight gain
drowsiness
dry mouth
increased cholesterol
extrapyramidal symptoms (rare)
increased blood sugar
|
|
gptkbp:usedFor
|
gptkb:generalized_anxiety_disorder
gptkb:major_depressive_disorder
bipolar disorder
schizophrenia
|
|
gptkbp:bfsParent
|
gptkb:Quetiapine_(off-label)
|
|
gptkbp:bfsLayer
|
7
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Quetiapine
|